Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
774.020.07%
QQQ
746.570.69%
BTC/USD
86333.440.2983%
DIA
517.820.38%
GLD
399.690.33%
TLT
81.840.06%

Damora Therapeutics Inc

DMRANASDAQ
Trade with Public
Trade with Public
$22.20
-0.66-2.87%
Last update: Sep 22, 2:16 PM
OverviewNewsEarnings ForecastPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Damora Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Damora Therapeutics (DMRA).

Price Target Range — 3 Quarters

Analyst Consensus — 5 Analysts

5Buy
Consensus RatingOutperform# Analysts5Avg. Consensus PT$44Upside to Avg. PT+99.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 30, 2026WedbushDavid NierengartenPT RaiseOutperform$35→$40
Jul 27, 2026JefferiesAkash TewariInitiateBuy$50
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40

Wedbush analyst David Nierengarten maintains Damora Therapeutics (NASDAQ:DMRA) with a Outperform and raises the price target from $35 to $40.
Benzinga Newsdesk

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

Top Wall Street analysts changed outlook on several top stocks. See all changes on analyst ratings page.
Avi Kapoor

This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Wall Street analysts change outlook on top stocks, including LIME, CIFR, BSP, DMRA, and ITG. Check analyst ratings page for full view.
Avi Kapoor

PRO
Jefferies Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $50

Jefferies analyst Akash Tewari initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a Buy rating and announces Price Target of $50.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Damora Therapeutics (NASDAQ:DMRA) with a Buy and maintains $45 price target.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $35 Price Target

Wedbush analyst David Nierengarten reiterates Damora Therapeutics (NASDAQ:DMRA) with a Outperform and maintains $35 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved